Published online Mar 24, 2016. doi: 10.5410/wjcu.v5.i1.24
Peer-review started: September 5, 2015
First decision: November 24, 2015
Revised: December 24, 2015
Accepted: January 5, 2016
Article in press: January 7, 2016
Published online: March 24, 2016
Processing time: 202 Days and 20.2 Hours
Urology has been on the forefront of technological advances in minimally invasive surgery, from laparoscopy to robot-assisted surgeries. As with all new technological advances in medicine, the results of new advances are compared to previously established gold standards. When it comes to robot-assisted urology, morbidity, oncological outcomes, and cost between the same surgeries performed in an open fashion vs with robot-assistance should be assessed. Because healthcare spending is increasingly under more scrutiny, there is debate on the cost effectiveness of robot-assisted surgeries given the high acquisition and maintenance cost of robotic systems. This articles aims to critically evaluate the cost effectiveness of robot-assisted surgeries for prostatectomies, cystectomies, and partial nephrectomies in the United States.
Core tip: Robot-assisted urologic oncologic surgeries offers significant amounts of benefit, with shorter length of stay, less blood loss and improved peri-operative quality of life. The high fixed cost of robot acquisition and maintenance is offset by increasing the number of robot cases per year, narrowing the gap in cost between robot-assisted surgeries and open surgeries. Cost effective analysis and cost benefit analysis of robot-assisted surgeries are difficult to assess given the difficulties with evaluating indirect costs. However, the measurable differences favor robot-assisted surgeries.